NEW YORK — Regeneron Pharmaceuticals (REGN) faces significant pressure on its flagship eye drug, Eylea, which accounted for more than 60 percent of its 2025 revenue. Biosimilar competition for Eylea is intensifying, with multiple entrants expected to erode market share and pricing power across global markets. This directly impacts REGN's primary revenue engine, which has seen its growth rate decelerate from double-digits to low single-digits in recent quarters as competitors gain traction.
Regenon's pipeline lacks a clear, near-term blockbuster capable of offsetting Eylea's impending revenue decline. While the company invests heavily in research and development, its late-stage assets in oncology and immunology have yet to demonstrate the market-moving potential required for sustained growth over the next five years. Analysts point to a dearth of late-stage candidates with multi-billion dollar peak sales potential. This creates uncertainty for future earnings expansion.
Despite recent market corrections, Regeneron's valuation does not fully account for the long-term competitive threats to Eylea and the uncertainty in its pipeline. The stock trades at a premium to some pharmaceutical peers based on historical performance rather than future growth prospects. Investors are increasingly prioritizing companies with innovative growth drivers and strong intellectual property protection, a category where REGN now struggles to maintain its leadership.
Eli Lilly and Company (LLY) offers a strong alternative for investors seeking growth in the pharmaceutical sector. Lilly's diabetes and obesity drugs, Mounjaro and Zepbound, continue to drive substantial revenue expansion, with demand consistently outstripping supply. These therapies represent a multi-billion dollar opportunity in a rapidly expanding global market, positioning Lilly as a clear leader in metabolic diseases.
Beyond its metabolic disease franchise, Lilly maintains a strong pipeline in neuroscience, oncology and immunology, providing additional long-term growth vectors. The company's consistent execution in clinical trials and strategic acquisitions support its current market leadership. Lilly's strong balance sheet and commitment to innovation make it a superior investment compared to Regeneron's more challenging outlook.
The broader pharmaceutical market has favored companies with strong patent protection and novel drug platforms. Eli Lilly's market capitalization has risen significantly over the past year, reflecting investor confidence in its growth trajectory. Analysts at major investment banks have set price targets for LLY ranging from $900 to $1,000, citing its dominant position in the GLP-1 agonist market. Regeneron, conversely, faces downward pressure on its own targets as Eylea's outlook dims.
